Palisade Bio, Inc. (PALI)
NASDAQ: PALI · Real-Time Price · USD
1.670
-0.100 (-5.65%)
At close: Dec 27, 2024, 4:00 PM
1.700
+0.030 (1.80%)
After-hours: Dec 27, 2024, 7:59 PM EST
Palisade Bio Employees
Palisade Bio had 9 employees as of December 31, 2023. The number of employees decreased by 3 or -25.00% compared to the previous year.
Employees
9
Change (1Y)
-3
Growth (1Y)
-25.00%
Revenue / Employee
n/a
Profits / Employee
-$1,562,778
Market Cap
2.22M
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2023 | 9 | -3 | -25.00% |
| Dec 31, 2022 | 12 | -1 | -7.69% |
| Dec 31, 2021 | 13 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| Aptevo Therapeutics | 40 |
| Matinas BioPharma Holdings | 32 |
| Biodexa Pharmaceuticals | 21 |
| Phio Pharmaceuticals | 9 |
| PainReform | 7 |
| IMAC Holdings | 4 |
| Bone Biologics | 2 |
| Salarius Pharmaceuticals | 2 |
PALI News
- 11 days ago - Palisade Bio Appoints Brian Feagan, MD, FRCPC, to its Clinical Advisory Board - GlobeNewsWire
- 15 days ago - Palisade Bio Announces Closing of $5 Million Underwritten Public Offering Priced At-Market Under Nasdaq Rules - GlobeNewsWire
- 16 days ago - What's Going On With Palisade Bio Stock On Thursday? - Benzinga
- 16 days ago - Palisade Bio Announces Pricing of $5 Million Underwritten Public Offering Priced At-Market Under Nasdaq Rules - GlobeNewsWire
- 25 days ago - Palisade Bio Announces Preliminary Data from Phase 1 Clinical Study of PALI-2108 for the Treatment of Moderate-to-Severe Ulcerative Colitis Appears to be Safe and Well Tolerated in Treated Subjects - GlobeNewsWire
- 5 weeks ago - Palisade Bio to Present Preclinical Results for PALI-2108 Demonstrating Engagement of Key Fibrotic Pathways of Crohn's Disease and Ulcerative Colitis (UC) - GlobeNewsWire
- 6 weeks ago - Palisade Bio Reports Third Quarter 2024 Financial Results and Outlines Key Accomplishments and Next Steps to Advance Lead Program PALI-2108 - GlobeNewsWire
- 2 months ago - Palisade Bio Announces Positive Data from Two Ex Vivo Translational Studies of PALI-2108 for the Treatment of Ulcerative Colitis - GlobeNewsWire